E. Gromnica-Ihle

Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis (2008)

Westhoff, G., Buttgereit, F., Gromnica-Ihle, E., Zink, A.

Objective. To describe the association between morning stiffness (MS) and early retirement in patients with early RA. Methods. The study used data from a prospective RA cohort of 916 RA patients with...

Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis (2008)

Schmidt, W. A., Seifert, A., Gromnica-Ihle, E., Krause, A., Natusch, A.

Objective. To describe characteristic ultrasound findings and clinical features of patients with newly diagnosed cranial and large-vessel (LV) GCA in a specialized ultrasound clinic. Methods. This...

Prognosis of large-vessel giant cell arteritis (2008)

Schmidt, W. A., Moll, A., Seifert, A., Schicke, B., Gromnica-Ihle, E., Krause, A.

Objective. The prognosis of large-vessel GCA (LV-GCA) has not yet been investigated. How does it compare to GCA without arm vasculitis (GCA controls)? Methods. Charts of 53 LV-GCA patients and 53 GCA...

Long-term immune reconstitution after autologous stem-cell transplantation for severe autoimmune diseases (2005)

Alexander, T, Massenkeil, G, Gromnica-Ihle, E, Burmester, GR, Radbruch, A, Arnold, R, ...

No abstract available.

Persistent clinical response to the anti-TNF-{alpha} antibody infliximab in patients with ankylosing spondylitis over 3 years (2005)

Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...

Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...

Persistent clinical response to the anti-TNF-{alpha} antibody infliximab in patients with ankylosing spondylitis over 3 years (2005)

Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...

Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...

Persistent clinical response to the anti-TNF-{alpha} antibody infliximab in patients with ankylosing spondylitis over 3 years (2005)

Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., ...

Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded...

Establishment of juvenile and tolerant immune systems in patients with autoimmune diseases treated with immunoablation and autologous stem cell therapy (2003)

Radbruch, A, Thiel, A, Kimmig, S, Alexander, T, Gromnica-Ihle, E, Hiepe, F, ...

No abstract available.

Long term immune reconstitution after immunoablation and autologous CD34 cell therapy in autoimmune diseases (2002)

Thiel, AT, Thiel, A, Alexander, T, Rosen, O, Gromnica-Ihle, E, Burmester, GR, ...

No abstract available.

Diagnosis of early Takayasu arteritis with sonography (2002)

Schmidt, W. A., Nerenheim, A., Seipelt, E., Poehls, C., Gromnica-Ihle, E.

Objective. Takayasu arteritis is a large‐vessel vasculitis that occurs predominantly in young females. The diagnosis is not usually established before arterial stenoses or occlusions are...

Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries (2002)

Schmidt, W. A., Gromnica-Ihle, E.

Objective. To determine the incidence of temporal arteritis (TA) in patients with polymyalgia rheumatica (PMR) using colour Doppler ultrasonography of the temporal arteries....

In vivo preactivated autoreactive Th cells in healthy individuals (2001)

Radbruch, A, Nitsch, S, Holzknecht, B, Gromnica-Ihle, E, Schneider, S, Hiepe, F, ...

No abstract available.

P1. Immunoablation with t cell depleted autologous peripheral blood stem cell rescue produces complete remission in thrombocytopenic purpura (TTP) recidivant and refractory to standard treatment

Espigado, I., Rodriguez, J., Carmona, M., Alonso, D., Rios, E., Perez-Hurtado, J., ...

Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis

Petrow, P, Wernicke, D, Schulze, W, Hummel, K, Brauer, R, Kriegsmann, J, ...

Objective: To study the pattern and cell type-specificity of collagenase 3, membrane-type 1 matrix metalloproteinase (MT1-MMP), and gelatinase A mRNA expression in the synovial membrane in rheumatoid...

Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis

Alten, R, Gromnica-Ihle, E, Pohl, C, Emmerich, J, Steffgen, J, Roscher, R, ...

Background: Leukotriene B4 (LTB4) has a key role in the pathophysiology of rheumatoid arthritis (RA).

Standard reference values for musculoskeletal ultrasonography

Schmidt, W, Schmidt, H, Schicke, B, Gromnica-Ihle, E

Objectives: To determine standard reference values for musculoskeletal ultrasonography in healthy adults.

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

Braun, J, Brandt, J, Listing, J, Zink, A, Alten, R, Burmester, G, ...

Objective: To obtain results of the second year extension of an original 3 month randomised, placebo controlled trial (and the 1 year extension study) assessing the use of infliximab, a monoclonal...

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

Zink, A, Listing, J, Kary, S, Ramlau, P, Stoyanova-Scholz, M, Babinsky, K, ...

Objective: To compare drug continuation rates in patients with rheumatoid arthritis who start on a biological agent and in a control group of patients with a change in disease modifying antirheumatic...